Switching from a first to a second tumour necrosis factor (TNF) alpha antagonist in patients with juvenile idiopathic arthritis

por Schmeling, H, Horneff, G
Publicado 2008

PReS-FINAL-2179: Efficacy and safety of adalimumab in pediatric patients with enthesitis related arthritis

por Burgos-Vargas, R, Tse, S, Horneff, G, Pangan, AL, Unnebrink, K, Anderson, JK
Publicado 2013

PReS-FINAL-2152: Biomarkers as predictors of early inactive disease in children with juvenile idiopathic arthritis

por Lavric, M, Weinhage, T, Klotsche, J, Horneff, G, Haas, JP, Minden, K, Foell, D
Publicado 2013

Safety and efficacy of tocilizumab in children with systemic juvenile idiopathic arthritis

por Horneff, G, Huppertz, I, Haas, P, Minden, K, Ganser, G, Hospach, A, Trauzeddel, R
Publicado 2015

Open label multicenter study of once weekly Etanercept 0.8 mg/kg in active polyarticular Juvenile idiopathic arthritis (JIA)

por Horneff, G, Minden, K, Foeldvari, I, Kuemmerle-Deschner, J, Thon, A, Girschick, H, Huppertz, HI
Publicado 2008

PReS-FINAL-2216: Biomarkers MRP8/14 and S100A12 correspond with flare and remission clinical status in Sojia patients in the AID-NET register

por Gohar, F, Husmann, E, Haas, PJ, Horneff, G, Wittkowski, H, Holzinger, D, Kallinich, T, Neudorf, U, Niehues, T, Lainka, E, Foell, D
Publicado 2013

Outcome of children with oligoarticular juvenile idiopathic arthritis compared to polyarthritis on methotrexate- data of the German BIKER registry

por Raab, A., Kallinich, T., Huscher, D., Foeldvari, I., Weller-Heinemann, F., Dressler, F., Kuemmerle-Deschner, J. B., Klein, A., Horneff, G.
Publicado 2021

PW02-040 - Low-penetrance NLRP3 variants

por Endres, T, Hofer, F, Goldbach-Mansky, R, Hoffman, HM, Blank, N, Krause, K, Rietschel, C, Horneff, G, Lohse, P, Kuemmerle-Deschner, J
Publicado 2013

PReS-FINAL-2331: Low-penetrance NLRP3 variants

por Endres, T, Hofer, F, Goldbach-Mansky, R, Hoffman, HM, Blank, N, Krause, K, Rietschel, C, Horneff, G, Lohse, P, Kuemmerle-Deschner, J
Publicado 2013

PW02-041 - Canakinumab treatment regimens in CAPS-patients

por Hofer, F, Endres, T, Kortus-Götze, B, Blank, N, Weißbarth-Riedel, E, Schuetz, C, Kallinich, T, Krause, K, Rietschel, C, Horneff, G, Kuemmerle-Deschner, J
Publicado 2013

PReS-FINAL-2224: Canakinumab treatment regimens in CAPS-patients

por Hofer, F, Endres, T, Kortus-Götze, B, Blank, N, Weißbarth-Riedel, E, Schütz, C, Kallinich, T, Krause, K, Rietschel, C, Horneff, G, Kuemmerle-Deschner, J
Publicado 2013

Phase III, multi-centre, randomised, double blind, Placebo-controlled study for treatment of juvenile ankylosing spondylitis (AS) with Adalimumab

por Horneff, G, Fitter, S, Huppertz, HI, Foeldvari, I, Kuemmerle-Deschner, K, Kuester, R, Tzaribacev, N, Thon, A, Borte, M, Ganser, G, Trauzeddel, R, Minden, K
Publicado 2011

Canakinumab treat-to target strategies increase complete response rate in CAPS

por Kuemmerle-Deschner, J, Hofer, F, Endres, T, Kortus-Goetze, B, Blank, N, Weißbarth-Riedel, E, Schuetz, C, Kallinich, T, Krause, K, Rietschel, C, Horneff, G, Benseler, SM
Publicado 2015

Reduction in missed school days and improvement in parent activity participation in children with juvenile idiopathic arthritis treated with abatacept

por Ruperto, N, Lovell, DJ, Li, T, Paz, E, Horneff, G, Huppertz, HI, Deslandre, CJ, Minden, K, Punaro, M, Nunez, AF, Sigal, L, Block, A, Covucci, A, Martini, A, Giannini, EH
Publicado 2008

PReS-FINAL-2140: Neutropenia with Tocilizumab (TCZ) treatment is not associated with increased infection risk in patients with systemic juvenile idiopathic arthritis (SJIA)

por De Benedetti, F, Brunner, HI, Baildam, E, Burgos-Vargas, R, Horneff, G, Huppertz, HI, Minden, K, Myones, BL, Onel, K, Wang, J, Bharucha, K, Lovell, D, Martini, A, Ruperto, N
Publicado 2013

Efficacy and safety of canakinumab, a long acting fully human anti-Interleukin-1β antibody, in systemic juvenile idiopathic arthritis with active systemic features: results from a...

por Ruperto, N, Brunner, H, Horneff, G, Quartier, P, Constantin, T, Berkun, Y, Erguven, M, Kallinich, T, Brik, R, Wulffraat, NM, Ferrandiz, MA, Rutkowska-Sak, L, Ozdogan, H, McCann, L, Lheritier, K, Preiss, R, Tseng, L, Martini, A, Lovell, DJ
Publicado 2011

Interleukin (IL)- 6 inhibition - Follow-up data of the German AID-registry(1)

por Bielak, M, Husmann, E, Weyandt, N, Haas, JP, Horneff, G, Lutz, T, Lilienthal, E, Kallinich, T, Tenbrock, K, Berendes, R, Dückers, G, Wittkowski, H, Weißbarth-Riedel, E, Heubner, G, Oommen, PT, Klotsche, J, Neudorf, U, Föll, D, Niehues, T, Lainka, E
Publicado 2015

German evidence and consensus based guidelines 2010 for the treatment of juvenile idiopathic arthritis (JIA)

por Dueckers, G, Guellac, N, Arbogast, M, Dannecker, G, Foeldvari, I, Frosch, M, Ganser, G, Heiligenhaus, A, Horneff, G, Illhardt, A, Kopp, I, Krauspe, R, Markus, B, Michels, H, Schneider, M, Singendonk, W, Sitter, H, Spamer, M, Wagner, N, Niehues, T
Publicado 2011

P01-008 – FMF genotype-phenotype correlations in Germany

por Jeske, M, Lohse, P, Kallinich, T, Berger, T, Rietschel, C, Holzinger, D, Kamlah, C, Lankisch, P, Berendes, R, Dückers, G, Horneff, G, Lilienthal, E, Haas, JP, Giese, A, Dressler, F, Berrang, J, Pütter, C, Braunewell, L, Neudorf, U, Niehues, T, Lainka, E
Publicado 2013

IL-6 blockade in systemic juvenile idiopathic arthritis – achievement of inactive disease and remission (data from the German AID-registry)

por Bielak, M., Husmann, E., Weyandt, N., Haas, J.-P., Hügle, B., Horneff, G., Neudorf, U., Lutz, T., Lilienthal, E., Kallinich, T., Tenbrock, K., Berendes, R., Niehues, T., Wittkowski, H., Weißbarth-Riedel, E., Heubner, G., Oommen, P., Klotsche, J., Foell, Dirk, Lainka, E.
Publicado 2018